1) ADHR Consortium : Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23.Nat Genet 26:345-348,2000
2) Shimada T, Mizutani S, Muto T, et al : Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98:6500-6505,2001
3) Benet-Pagès A, Lorenz-Depiereux B, Zischka H, et al : FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462,2004
4) Shimada T, Hasegawa H, Yamazaki Y, et al : FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435,2004
5) Shimada T, Kakitani M, Yamazaki Y, et al : Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568,2004
6) Sitara D, Razzaque MS, Hesse M, et al : Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432,2004
7) Urakawa I, Yamazaki Y, Shimada T, et al : Klotho converts canonical FGF receptor into a specific receptor for FGF23.Nature 444:770-774,2006
8) Kuro-o M, Matsumura Y, Aizawa H, et al : Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390:45-51,1997
9) Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, et al : The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008,2007
10) Farrow EG, Davis SI, Summers LJ, et al : Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20:955-960,2009
11) Fukumoto S, Martin TJ : Bone as an endocrine organ. Trends Endocrinol Metab 20:230-236,2009